NovoCure Limited
In the published model solve dated 2026-Q2, anchored at $16.06, NovoCure Limited (NVCR) is priced for +2.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• NovoCure sells Tumor Treating Fields, a wearable device therapy for cancer marketed as Optune, and the core franchise carries device-like economics with a gross margin around 74%, even though the company still operates at a loss. [Source: NovoCure FY2024 10-K] • The clearest risk is that growth in new indications has disappointed: Optune Lua for lung cancer generated only $3 million in Q1 2026, and the company bears the financial risk of getting paid by insurers in most markets. [Source: NovoC
Is NVCR overvalued? See what's priced in →
211 institutional managers reported holding NVCR in 13F filings for the quarter ended 2026-03-31. Together they hold about 86% of the company; the top 10 hold 61%. 31 opened new positions that quarter. Held by FMR (Fidelity), BlackRock, Vanguard Group, among others. On the short side, 9.7M shares were sold short as of the 2026-06-15 count, about 8% of shares outstanding (6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
NVCR's share count grew 10.3% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at NVCR over the trailing three years: 2025: 4 buys totaling $1.23M. 19 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
NVCR's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-28 | -17.4% | -51.6% |
| 2023-10-27 | -10.3% | +18.3% |
| 2024-02-23 | -2.7% | -16.9% |
| 2024-05-03 | +15.8% | +13.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
NVCR's latest 8-K filings: 2026-07-23 (items 2.02, 9.01); 2026-06-30 (items 7.01, 9.01); 2026-06-18 (items 7.01, 9.01); 2026-06-05 (items 5.02, 5.07, 9.01); 2026-04-30 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.